



Oxford University Hospitals  
NHS Foundation Trust



# “**Imaging**-derived **physiology**” una soluzione per integrare i due approcci?

Giovanni Luigi De Maria MD, PhD, FESC  
Interventional Cardiology Consultant  
AMiIC Catheterization Laboratory Clinical Lead  
Oxford Heart Centre – John Radcliffe Hospital  
Oxford, UK

 GiovanniLuigi.demaria@ouh.nhs.uk

 @GiovanniLuigiD1

 Giovanni Luigi De Maria



CeNS, Genova 14.04.2023

## Conflicts Of Interest

Within the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) listed below.

### Affiliation/Financial Relationship

Grant/Research Support

Consulting Fees/Honoraria

### Company

Miracor Medical SA, Abbott, Philips, Medtronic, Terumo, Medis Medical Imaging, Opsens

Miracor Medical SA, Abbott

# Agenda

- *Why Imaging-derived Physiology*
- *Basic Principles of Imaging-derived Physiology*
- *Overview of main indices: Modalities of Imaging Derived Physiology*
- *Clinical Applications & Supporting Evidence*


# *Why Imaging-derived Physiology?*

# 2018 ESC/EACTS Guidelines on myocardial revascularization


Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
When evidence of ischaemia is not available, FFR or iwFR are recommended to assess the haemodynamic relevance of intermediate-grade stenosis. <sup>15,17,18,39</sup>	<b>I</b>	<b>A</b>
FFR-guided PCI should be considered in patients with multivessel disease undergoing PCI. <sup>29,31</sup>	<b>IIa</b>	<b>B</b>

**BUT**

FFR adoption world-wide




*Gottberg M et al JACC 2017*



*ISIS Survey- Toth G et al Circ Intv 2014*

# Total PCI activity all UK



Total PCI Procedures


PCI pmp

97,765 PCIs  
1,460 pmp

1,548

# Additional Interventional Coronary Techniques

All cases: Diagnostic only + when part of a PCI procedure



Number of Procedures

20% of all PCI and Diagnostic only  
Up to 60% LMS PCI



# Why still sub-optimal diffusion of FFR

## Technique-related (the way FFR is measured)

- Additional procedural time
- Additional vessel instrumentation & manipulation
- Additional cost (no reimbursement in some countries)
- Patient's discomfort (adenosine-related)




# *Imaging-derived Physiology: Basic Principles*




# Imaging Based Indices

*(Anatomy-derived physiology)*


## 1 Acquisition of Images



## 2 Development of a 3D Model



## 3 Application of CFD or Fluid Dynamic Equations



# Imaging Based Indices







(Anatomy-derived physiology)

## Computational Flow Dynamics (CFD)

Several hours


< 10 minutes

- High computational power
- Long calculation times




**FFR<sub>CT</sub>**

*Koo B et al  
JACC 2011*




**vFFR (virtual FFR)**

*Morris P et al  
JACC Intv 2013*



**vFAI**

*Papafaklis M et al  
EuroIntervention 2013*




**FFR<sub>QCA</sub>**


*Tu S et al  
JACC Intv 2014*

# *Imaging Derived Physiology: Overview of main indices & Validation Studies*

# CTCA Derived Physiology




FFR<sub>CT</sub>




C- FFR

TOSHIBA




CT FFR




CT  $\mu$ FR

# Angiography Derived Physiology



QFR




vFFR

CATHWORKS




FFRangio

# Intravascular Imaging Derived Physiology




OCT derived - OFR




IVUS derived - UFR



# CTCA Derived Physiology




FFR<sub>CT</sub>




C- FFR

TOSHIBA




CT FFR




CT  $\mu$ FR

# Angiography Derived Physiology



QFR




vFFR




FFRangio

# Intravascular Imaging Derived Physiology



OCT derived - OFR




IVUS derived - UFR


# Angiography Derived Physiology








## FAVOR I (n= 73)



## FAVOR II Europe-Japan (n= 272)






## FAVOR II China (n= 304)



	Estimate, % (95% CI)
Accuracy	92.7 (89.3-95.3)
Sensitivity	94.6 (88.7-98.0)
Specificity	91.7 (87.1-95.0)
PPV	85.5 (78.0-91.2)
NPV	97.1 (93.7-98.9)



# Angiography Derived Physiology

## FAST study – 100 pts



Masdjedi K et al EuroIntervention 2020

## FAST II study [Multicenter]– 344 pts




Masdjedi K et al EuroIntervention 2022




# Angiography Derived Physiology


## FFRangio CATHWORKS





Witberg et al – (multicentre retrospective ) 500 pts, 700 vessels



FAST-FFR study – (multicentre) 301 pts, 319 vessels




Fearon W et al Circulation 2019



Witberg G et al JACC Cardiovasc Intv 2020

# Angiography Derived Physiology

**Medis** Medical Imaging  
Imaging Solutions in a Heartbeat



QFR

3D Model from 2 views

BP conditions fixed

Flow "measured" as derived from **TIMI frame count**


Single vessel

No Bifurcation

No Co-Registration

Manual

**Caas**  
vFFR



vFFR

3D Model from 2 views

*Input aortic BP*

Flow not "measured" proprietary algorithm

Single vessel

No Bifurcation

No Co-Registration

Manual

**CATHWORKS**



FFRangio

3D Model from *3 views*

*Input aortic BP*

Drop Pressure from "lump model"  
*Electrical resistance*

Multiple vessels

Bifurcation

No Co-Registration

Manual

**RainMed**



FlashAngio caFFR

3D Model from 2 views

*"Beat by Beat" aortic BP*

Flow not "measured" proprietary algorithm

Single vessel

No Bifurcation

No Co-Registration

Manual



$\mu$ FR

3D Model from *1 view*

BP conditions fixed

Flow "measured" as derived from **TIMI frame count**


Single vessel

Bifurcation


Co-Registration

AI-Based


# CTCA Derived Physiology




FFR<sub>CT</sub>




C- FFR




QFR



vFFR




OCT derived - OFR




IVUS derived - UFR

# Angiography Derived Physiology

# Intravascular Imaging Derived Physiology



CT FFR



CT  $\mu$ FR




FFRangio



# Intravascular Imaging Derived Physiology

## UFR



N = 94 pts, 97 vessels


A

**Table 3. Diagnostic Performance of UFR- and IVUS-Derived MLA to Identify  $FFR \leq 0.80$**

	UFR $\leq 0.80$	MLA $\leq 2.01 \text{ mm}^2$
Accuracy, % (95% CI)	92 (87-96)	83 (78-89)
Sensitivity, % (95% CI)	91 (82-96)	89 (81-95)
Specificity, % (95% CI)	96 (90-99)	78 (68-87)
PPV, % (95% CI)	96 (89-99)	81 (71-88)
NPV, % (95% CI)	91 (93-96)	88 (78-94)

Yu W et al Circ Intv 2021



## OFR



N = 118 pts, 125 vessels

	OFR $\leq 0.80$	MLA $\leq 1.89$
Accuracy, % (95% CI)	90 (84-95)	74 (67-82)
Sensitivity, % (95% CI)	87 (77-94)	78 (66-87)
Specificity, % (95% CI)	92 (82-97)	71 (58-82)
PPV, % (95% CI)	92 (82-97)	73 (61-83)
NPV, % (95% CI)	88 (77-95)	76 (63-86)
LR+ (95% CI)	10.8 (4.6-25.2)	2.7 (1.8-4.0)
LR- (95% CI)	0.1 (0.1-0.3)	0.3 (0.2-0.5)

N = 181 pts; 212 vessels



	OFR $\leq 0.80$	OCT-derived MLA $\leq 1.88$	QFR $\leq 0.80$	3D QCA-derived %DS $> 50.7\%$
Accuracy	92 (88-95)	76 (70-82)	87 (83-92)	75 (69-80)
Sensitivity	86 (77-93)	79 (69-87)	88 (79-94)	74 (64-83)
Specificity	95 (90-98)	74 (66-81)	87 (80-93)	75 (66-82)
PPV	92 (84-97)	67 (57-76)	82 (73-90)	66 (56-76)
NPV	91 (85-95)	84 (76-90)	92 (85-96)	81 (73-88)

# Applications

**#1 : Defining Indication for Stenting**

**#2 : Assessing final PCI results**

**#3 : Define Pattern & Distribution of Atherosclerosis**

**#4 : Planning PCI strategy**

**#5 : Optimising PCI result**






# FAVOR III CHINA




- 3825 Patients referred for PCI (stable CAD or > 72h NSTEMI-ACS)
- Stenosis Diameter 50-90%

	QFR-guided group (n=1913)	Angiography-guided group (n=1912)	p value
Radial artery approach	1885 (98.5%)	1869 (97.8%)	0.071
PCI performed	1731 (90.5%)	1895 (99.1%)	<0.0001
Drug-eluting stents placed	1667 (87.1%)	1812 (94.8%)	<0.0001
Drug-coated balloon angioplasty	55 (2.9%)	58 (3.0%)	0.77
Non-drug-coated balloon angioplasty	9 (0.5%)	25 (1.3%)	0.0049
Number of stents placed per patient	1.45 (1.02)	1.58 (0.97)	<0.0001
Stent length, mm	42.7 (26.3)	41.9 (26.3)	0.36
Stent diameter, mm	3.03 (0.41)	3.01 (0.41)	0.34
Patients with intended vessel deferral or unintended vessel treatment	445 (23.3%)	119 (6.2%)	<0.0001

**MACE = Death, All MI, Ischaemia Driven Revasc**



**MACE = Death, MI (no periprocedural), Ischaemia Driven Revasc**



# Superior to Angiogram .... But Equivalent to wire-based FFR?



2000 patients randomized to QFR guidance

vs

wb-FFR guidance



2228 patients randomized to vFFR guidance

vs


wb-FFR guidance



## **Application #2: Assessing Final PCI result**

N = 1395 pts, 1685 vessels


### B Post-PCI QFR



Number at Risk:

> 0.80	1621	1606	1599	1585	1571	1557	1551	1546	1542
≤ 0.80	64	61	60	58	56	53	53	53	53


N = 602 pts, 751 vessels



## **Application #3: Defining pattern of atherosclerosis**


N = 1003 pts, 1444 vessels **ALL with QFR < 0.80**

### A Pre-PCI QFR-PPG index



Number at Risk:

> 0.78	885	876	873	868	862	856	853	851	849
≤ 0.78	800	791	786	775	765	754	751	748	746





# Revascularization with successful stent implantation






Post-PCI measurement of QFR → **QFR value >0.89**

Low rate of adverse events and need of repeat revascularization

**QFR value ≤0.89**



3-time increase in the risk of VOCE  
Adjusted HR 2.91, 95% CI 1.63-5.19

Identification of the site of QFR drop




# Application #4: Planning PCI


# LEAVE FOCAL LESION



RESIDUAL QFR 0.76





RESIDUAL QFR 1.00




RESIDUAL QFR 0.95


# TREAT SERIAL LESIONS



RESIDUAL QFR 0.87




RESIDUAL QFR 0.81



RESIDUAL QFR 0.97

# AQVA study



**Primary Endpoint:** rate of vessels with post-PCI QFR < 0.90

ARTICLE IN PRESS



JACC: CARDIOVASCULAR INTERVENTIONS  
© 2023 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION  
PUBLISHED BY ELSEVIER

VOL. ■, NO. ■, 2023

## QFR-Based Virtual PCI or Conventional Angiography to Guide PCI


### The AQVA Trial

Simone Biscaglia, MD,<sup>a</sup> Filippo Maria Verardi, MD,<sup>a</sup> Matteo Tebaldi, MD,<sup>a</sup> Vincenzo Guiducci, MD,<sup>b</sup> Serena Cagliioni, MD,<sup>a</sup> Roberta Campana, MD,<sup>a</sup> Antonella Scala, MD,<sup>a</sup> Andrea Marrone, MD,<sup>a</sup> Graziella Pompei, MD,<sup>a</sup> Federico Marchini, MD,<sup>a</sup> Davide Scancarello, MD,<sup>a</sup> Gianluca Pignatelli, MD,<sup>b</sup> Sergio Musto D'Amore, MD,<sup>b</sup> Iginio Colaiori, MD,<sup>b</sup> Pierluigi Demola, MD,<sup>b</sup> Luigi Di Serafino, MD,<sup>c</sup> Carlo Tumscitz, MD,<sup>a</sup> Carlo Penzo, MD,<sup>a</sup> Andrea Erriquez, MD,<sup>a</sup> Marco Manfrini, BSc,<sup>d</sup> Gianluca Campo, MD<sup>a</sup>





# P4 RCT



**Hypothesis:** A CT-guided PCI strategy is **non-inferior** to IVUS guided PCI with respect to **MACE**

# Application #5: Optimizing PCI results




# Optical flow ratio for assessing stenting result and physiological significance of residual disease

Daixin Ding<sup>1,2</sup>, MSc; Wei Yu<sup>1</sup>, BSc; H el ene Tausin<sup>3</sup>, PhD; Giovanni Luigi De Maria<sup>4</sup>, MD, PhD; Peng Wu<sup>1</sup>, BSc; Fan Yang<sup>1</sup>, BSc; Rafail A. Kotronias<sup>4</sup>, MBChB, MSc; Dimitrios Terentes-Printzios<sup>4</sup>, MD, PhD; Mathias Wolfrum<sup>4</sup>, MD; Adrian P. Banning<sup>4</sup>, MBBS, MD; Nicolas Meneveau<sup>3</sup>, MD, PhD; William Wijns<sup>2</sup>, MD, PhD; Shengxian Tu<sup>1,5\*</sup>, PhD

1. Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China; 2. The Lambe Institute for Translational Medicine and C URAM, National University of Ireland Galway, Galway, Ireland; 3. Department of Cardiology, University Hospital Jean Minjoz, Besan on, France; 4. Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; 5. Department of Cardiology, Fujian





N = 155 pts (DOCTORS & OxOPT studies)


	Post-PCI OFR $\leq 0.90$
Accuracy, % (95% CI)	84 (77-91)
Sensitivity, % (95% CI)	61 (44-77)
Specificity, % (95% CI)	93 (86-98)
PPV, % (95% CI)	79 (59-92)
NPV, % (95% CI)	86 (77-92)





# OFR





\*Lauri FM et al EHI Suppl 2018